Trial Profile
Randomized, multicenter, open-label, comparative study on neuroprotective effects of zonisamide (Trerief), anti-parkinsonian drug, in patients with early Parkinson's disease: Evaluation by functional PET (positron emission tomography) images
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 12 Mar 2019
Price :
$35
*
At a glance
- Drugs Zonisamide (Primary) ; Decarboxylase inhibitors; Levodopa
- Indications Parkinson's disease
- Focus Pharmacodynamics
- Acronyms TIPPS
- 07 Mar 2019 Planned End Date changed from 31 Mar 2021 to 31 Mar 2019.
- 07 Mar 2019 Status changed from active, no longer recruiting to discontinued.
- 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.